Covalon receives FDA approval for Collagran, Collagran Ag wound dressing

New York, April 26 - Covalon Technologies Ltd. said the Food and Drug Administration approved its Collagran and Collagran Ag collagen-based wound dressings for use in the United States.

The dressings, when applied to decubitus and other wounds, create a beneficial wound healing environment.

Collagran and Collagran Ag inhibit the activity of matrix metalloproteases that are known to be detrimental to optimal wound healing. The dressings absorb wound exudates to form a soft and conformable collagen-based, hydrophilic pad that is gas permeable.

Furthermore, Collagran Ag provides antimicrobial silver ions that provide a biocidal microbial barrier in the dressing.

Collagan and Collagran Ag are indicated for use on pressure ulcers, diabetic ulcers, venous ulcers, first and second degree burns, donor and graft sites, abrasions and lacerations, dehisced surgical wounds and traumatic wounds healing by secondary intention.

Covalon is a Mississauga, Ont., medical products company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.